Ontology highlight
ABSTRACT:
SUBMITTER: Fernandez B
PROVIDER: S-EPMC6792036 | biostudies-literature | 2019 Oct
REPOSITORIES: biostudies-literature
The Biochemical journal 20191001 19
Leucine-rich repeat kinase 2 (LRRK2) is a promising therapeutic target for the treatment of Parkinson's disease (PD), and orally bioavailable, brain penetrant and highly potent LRRK2 kinase inhibitors are in early stages of clinical testing. Detection of LRRK2 phosphorylation, as well as phosphorylation of Rab10, a LRRK2 kinase substrate, have been proposed as target engagement biomarkers for LRRK2 inhibitor clinical trials. However, these readouts do not seem able to stratify patients based on ...[more]